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Off-label prescribing is an integral part of contemporary medicine. Many patients benefit when
they receive drugs or devices under circumstances not specified on the label approved by the
Food and Drug Administration (FDA). An off-label use may provide the best available
intervention for a patient, as well as the standard of care for a particular health problem. In
oncology, pediatrics, geriatrics, obstetrics, and other practice areas, patient care could not
proceed without off-label prescribing.1 When scientific and medical evidence justify off-label
uses, physicians promote patients’ interests by prescribing products off label.
Off-label prescribing can also harm patients, however. The potential for harm is greatest when
an off-label use lacks a solid evidentiary basis. A 2006 study examining prescribing practices
for 169 commonly prescribed drugs found high rates of off-label use with little or no scientific
support.2 Researchers examining off-label use in U.S. children’s hospitals concluded, “[W]e
still have incomplete knowledge about the safety and efficacy of many medications commonly
used to treat children across a range of drug classes and clinical diagnoses.”3 More than half
the respondents in a survey of academic medical centers reported that innovative off-label
prescribing raised concerns in their institutions, such as lack of data, costs, and unfavorable
risk-benefit ratios.4 When substantial uncertainty exists about off-label applications, patients
are at risk of receiving harmful or ineffective treatments.
Legal authorities recognize physicians’ discretion to prescribe products off label.5 In the
existing regulatory framework, once the FDA approves a product for marketing, physicians
may prescribe it for indications or patient populations not included on the label. They may also
prescribe drugs at dosages or using methods of administration not specified on the label.6
Omission from the approved label does not mean that the FDA disapproves of an off-label use,
it simply indicates that the agency has not reviewed that use. Of course, like other parts of
medical practice, off-label prescribing can lead to malpractice liability if it fails to conform to
accepted standards of care.7
In a perfect world, all uses of drugs and devices would be supported by solid research. The
existing regulatory system fails to impose this high standard, however, and the private sector
often lacks incentives to conduct rigorous evaluations of off-label uses. In the current situation,
the medical community has primary responsibility for determining when off-label prescribing
is appropriate for patients. But appropriate off-label prescribing can be challenging for
physicians today, because of time pressures, information overload, and the involvement of
industry in research and education about off-label uses.
Responsible off-label prescribing requires physicians to: (1) evaluate whether there is sufficient
evidence to justify an off-label use; (2) press for additional information and research when
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adequate evidence is lacking; and (3) inform patients about the uncertainties and potential costs
associated with off-label prescribing. Policy efforts are also needed to improve the quality of
off-label prescribing. Federal authorities should systematically monitor patient responses to
off-label uses, regularly collect and publicize information about off-label uses, and consider
proposals to regulate certain off-label uses, as well as other proposed policy measures that
could decrease risky and ineffective off-label prescribing. In the remainder of this article, we
examine the current federal policies governing off-label prescribing, ethical standards
governing off-label prescribing, and policy reforms to promote patient and public interests in
evidence-based off-label prescribing.
The Existing Regulatory Structure
The Initial Approval Process
The Food, Drug, and Cosmetic Act (FDCA) governs interstate distribution of medical products.
8 Manufacturers may distribute drugs and certain devices for commercial use only after the
FDA has approved the products as safe and effective for their intended use. As part of the
product approval process, sponsors submit detailed information about trials done for specific
indications in specific populations. The process “can involve dozens of FDA scientists poring
over extensive databases of studies in animals, toxicologic evaluations, and clinical trials.”9
With the help of outside advisers, FDA officials evaluate safety and effectiveness and
determine whether the probability and magnitude of potential benefits are sufficient to justify
a product’s risks.
Although the FDA review process is far from perfect and could be improved,10 it generally
produces highquality information that enhances clinical practice. In most cases, the FDA
review process gives physicians a reasonable evidentiary basis for on-label prescribing. But
the initial FDA review fails to answer whether a product should be used off label. A product
may be safe and effective for one indication, but could present a different risk-benefit ratio for
another indication. Products found safe and effective for adult trial participants may not work
safely and effectively in children or elderly people. Drugs can have different effects at different
dosages or with different methods of administration.
When FDA officials approve a product, they approve a specific label for that product, too. The
label includes information about the approved indications for product use, as well as the
approved dosage, method of administration, and patient population. Federal law permits the
use of marketed products in wider circumstances, however. Physicians may prescribe drugs
and devices in situations not covered by the approved label. The FDCA authorizes the FDA to
regulate manufacturers’ activities in interstate commerce, including advertising, but does not
authorize the agency to regulate physicians’ behavior.11
Federal officials, medical organizations, and others defend the current approach by citing
benefits to patients. They say that patients’ access to potentially helpful treatments should not
be delayed until an off-label use receives formal FDA approval.12 Consistent with this view,
Medicare, Medicaid, and private insurers reimburse for off-label uses when there is some
evidence to support such uses.13
Off-Label Promotion
Although physicians are free to prescribe off-label, the federal regulatory system imposes
constraints that affect off-label use. Consistent with its jurisdictional authority, the FDA
controls manufacturers’ product marketing. To promote the use of a product according to its
label, manufacturers may advertise, distribute other forms of promotional material, and solicit
business through their sales representatives. In contrast, the FDA restricts manufacturers’
freedom to promote off-label uses. The FDCA and FDA regulations prohibit manufacturers
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from distributing in interstate commerce products intended for off-label uses. According to the
FDA, approved drugs that are promoted for an unapproved use are misbranded, and devices
promoted for unapproved uses are adulterated and misbranded.14
During the 1990s, Congress amended the FDCA to permit a limited form of off-label
promotion. The amendments allowed manufacturers to distribute to physicians reprints of so-
called “enduring materials,” defined as articles from peer-reviewed journals and reference
books, that discussed off-label uses.15 A separate FDA guidance allowed manufacturers to
provide financial support to educational programs at which speakers discussed off-label uses,
as long as the programs were organized by independent entities.16 At the same time, however,
the amendments and guidance imposed a number of conditions on these activities. For example,
the FDCA amendments required manufacturers distributing enduring materials to certify that
they would seek FDA approval for the relevant off-label use or obtain an agency exemption
from the requirement (because, for example, the required studies would be too burdensome for
an off-label use serving a very small patient population). They also had to submit the enduring
materials for FDA review at least 60 days before distributing them to physicians.
Manufacturers’ statements about their products qualify as commercial speech, and the First
Amendment to the U.S. Constitution has been interpreted to require giving them some freedom
to communicate about off-label uses. In the late 1990s, a federal court found that the above
statutory and FDA provisions on off-label promotion were more restrictive than necessary to
advance the government’s interest in maintaining incentives for manufacturers to obtain FDA
approval for off-label uses.17 According to the court, some of the limitations on promotion
unnecessarily abridged protected speech rights. The judge said the government could require
manufacturers to disclose their financial interests and the fact that the product uses discussed
in the materials and educational sessions were not FDA approved. The agency could not enforce
several other restrictions, however, such as the requirements to seek FDA approval for the off-
label uses and FDA review of the materials on off-label uses.
The government appealed this decision, but in the appellate argument portrayed the contested
limitations on promotion as merely a “safe harbor” for manufacturers’ conduct, rather than as
requirements the agency intended to enforce.18 As a result, the case was dismissed without
establishing clear constitutional boundaries for government restrictions on commercial speech
about off-label uses.19
In early 2009, the FDA issued a new guidance on distribution of enduring materials addressing
off-label uses,20 but its constitutionality and policy impact remain uncertain. In a later part of
the essay, we discuss the current debate over federal efforts to limit off-label promotion and
question whether such efforts are the best way to promote public health interests in appropriate
off-label prescribing.
Supplemental Approval and Industry
Decision-Making—Although the specifics remain unclear, courts are likely to uphold the
government’s authority to impose some restrictions on off-label promotion, such as disclosure
requirements and prohibitions on consumer advertising. If this prediction is accurate, medical
product manufacturers seeking to engage in the full range of promotional activities will have
to secure from the FDA supplemental approval to add new uses to the approved label.21 Some
information needed to evaluate a supplemental application may come from the initial product
approval studies, but manufacturers must also submit additional data demonstrating the
product’s effectiveness for the new use.
Drug and device companies determine what uses to emphasize in the initial product review
process and make choices shaped by market forces, such as the size of the potential patient
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population.22 Market forces also influence companies’ decisions after their products gain
initial FDA approval. In some cases, profits from off-label uses may be sufficient to deter
manufacturers from seeking supplemental approval of a new product use.23 Company officials
may prefer to invest their resources in developing new drugs rather than sponsoring costly trials
that might (or might not) demonstrate the safety and effectiveness of new uses for already-
approved products.
Federal legislation has altered this situation by extending market exclusivity periods for
manufacturers evaluating products in certain populations commonly treated off label, such as
children24 and patients with rare diseases,25 but there are still many situations in which
companies lack financial incentives to pursue supplemental approval for new uses. Products
may be beneficial when used in ways that deviate from the label, but because neither the FDA
nor the private sector evaluates off-label uses in a systematic and transparent way,26 this
determination is often left to the medical community.
Ethical Standards
The ethical justification for off-label prescribing is that it can provide the best available therapy
for a particular patient. This contrasts with the ethical justification for conducting clinical trials,
which is to develop new therapies or clarify the best use of existing treatments for future
patients.27 Investigators often test off-label uses in formal research and, as we discuss below,
there are often ethical reasons to conduct such tests. But clinical off-label prescribing has a
therapeutic purpose and individual patient interests should guide such use.
In an effort to guide professional practice, a few medical organizations have issued policies on
off-label prescribing. The American Medical Association supports off-label use “when such
use is based on sound scientific evidence and sound medical opinion.”28 Similarly, the
American Academy of Pediatrics (AAP) Committee on Drugs endorses off-label prescribing
“based on sound scientific evidence, expert medical judgment, or published literature” and
“done … in the best interest of the patient.”29 The AAP Committee on Drugs also recognizes
an obligation to promote knowledge about off-label uses: “Physicians who choose to prescribe
a medication with limited pediatric data have a public and professional responsibility to assist
in the systematic development of the information about that drug for the benefit of other
patients.”30
Implicit in these advisory statements are two ethical considerations relevant to off-label
prescribing: (1) evaluating the existing evidence for off-label prescribing; and (2) collecting
information and conducting research when there is inadequate evidence about an off-label use.
A third consideration addresses disclosure to patients: what should physicians tell patients
about off-label interventions? In this section, we examine these considerations and apply them
to different categories of off-label prescribing, with the goal of helping physicians exercise
appropriate ethical judgment about off-label prescribing.
Evaluating the Evidence for Off-Label Uses
Off-label uses can be supported by different levels of evidence. Authorities recognize a
hierarchy of scientific and clinical evidence that can justify medical interventions. Typically
at the top are large randomized controlled trials (RCTs), followed by smaller RCTs, cohort
studies, case-control studies, poorly controlled or uncontrolled studies, case reports, and expert
opinion.31 Off-label prescribing can also be a logical extension of an approved use, as when a
drug approved for one condition is prescribed for another condition that has genetic or
physiologic similarities to the first.32 Physicians may prescribe a drug approved for one
indication to patients with less or more serious forms of the condition or for conditions causing
similar symptoms.33 Off-label applications may emerge through an organized research process
Dresser and Frader Page 4













or through “field discovery,” in which clinicians identify new applications as they care for
patients.34
Compendia, such as the American Hospital Formulary Service Drug Information35 and
DrugDex,36 evaluate and rate the evidence supporting specific off-label uses. The Agency for
Healthcare Research and Quality offers up-to-date summaries of the scientific evidence on
some off-label applications.37 At least one independent, not-for-profit professional
organization provides assessments of off-label uses.38 Peer-reviewed medical journals also
supply credible support for off-label uses.39 These resources can be useful, but offer clear
guidance only after high-quality research has evaluated a particular off-label use.40 Moreover,
the evaluations are not as rigorous as FDA review, for they typically involve fewer people and
a less comprehensive data analysis than the FDA requires.41 A recent review of Medicare-
approved compendia governing reimbursement for off-label anticancer chemotherapies found
the compendia lacking in consistency, quality, transparency, and timeliness.42
The medical product industry’s influence on research and education about off-label
applications can complicate physicians’ assessment of the evidence supporting off-label
prescribing. As noted earlier, the law permits manufacturers to engage in limited promotion of
products for off-label uses and, as discussed below, some form of promotion is likely to be
permitted in the future. Allowing manufacturers to distribute peer-reviewed materials and to
sponsor educational programs can help physicians learn about potentially beneficial off-label
uses. Yet manufacturers at times violate the letter or spirit of the rules requiring independent
and high-quality information, often with the assistance of physicians whose judgment may be
clouded by the compensation they receive for favorable presentations about off-label uses.43
A well-known example is the case involving off-label promotion of gabapentin, in which
company representatives subverted the rules by providing financial benefits to researchers and
physicians willing to convey positive views of off-label applications.44 Product manufacturers
may also exercise undue control over studies of off-label uses, through influencing study
design, data analysis, and publication content.45 Manufacturers may fail to publicize studies
with unfavorable findings, as well.46 For these reasons, physicians must closely scrutinize the
quality of industry-funded studies and presentations supporting off-label uses.
Although industry-sponsored research and education may encourage questionable off-label
prescribing, industry is not solely responsible for such prescribing. Studies suggest that many
physicians rely on experience, anecdotal reports, and opinion leaders to guide their treatment
decisions, often failing to demand solid evidence for their prescribing choices.47 This approach
to clinical knowledge can encourage inappropriate off-label prescribing even in the absence
of industry encouragement for it.48
The justification for off-label prescribing is strongest when rigorous research supports it.
Support that rests on other forms of evidence may also be sufficient, depending on the
circumstances. Below we discuss different off-label uses that can be justified by
unconventional evidence. In most cases, however, physicians should seek to develop a solid
research basis for off-label prescribing.
Collecting Information and Conducting Research
When an off-label use lacks an adequate evidentiary basis, the medical community should work
to rectify the situation. High-quality evidence about off-label applications not only protects
patients from harmful and ineffective interventions, it increases their access to beneficial
treatments. Public and private insurers are more likely to cover off-label uses that are supported
by solid evidence.49 Indeed, Medicare and other drug plans may deny payment when off-label
uses are not included in one of the major drug compendia.50 High-quality research indicating
that off-label uses are safe and effective can also encourage manufacturers to obtain FDA
Dresser and Frader Page 5













approval for new uses, which in turn produces a more informative label and increases patient
access to the product.51
Professional organizations and the academic community should actively identify emerging off-
label uses and gather information about such uses. As physicians learn about patient responses
to off-label uses, they should share information about side effects and outcomes with colleagues
through publications, presentations, and other methods of communication.52 They should also
alert manufacturers and the FDA to any adverse events associated with an off-label use.53
Medical journals and websites should promote communication by setting aside space for
reports about emerging off-label applications.54 Health care institutions should develop
policies on off-label prescribing and exchange information about positive and negative
experiences with off-label applications.55
The medical community should also promote necessary research about off-label uses. If
innovative use of a drug or device suggests that an off-label use has benefits, formal study
should commence.56 As the AAP Committee on Drugs observes, “Although [important] uses
are often discovered through off-label therapeutic use, confirmation of efficacy and safety in
formal studies is usually required.”57 If members of the profession think that an off-label use
is developing without adequate evidentiary support or examination of potential harms, they
should urge manufacturers to sponsor the needed research,58 or seek government or other
independent support for it.59
Informing Patients
There is debate over whether physicians should tell patients when a drug or device is prescribed
for an off-label use. A 2006 poll suggests that much of the U.S. public is confused and
ambivalent about off-label prescribing, with about half the respondents believing that
physicians are permitted to prescribe drugs only for on-label indications and about half
believing that physicians should be prohibited from prescribing drugs for off-label indications.
60 These findings suggest that explaining off-label regulatory status and its significance in
particular situations could be a complicated task.
Some commentators argue that information about off-label status is less important than
information about the evidence that supports a product’s use in an individual patient’s case.
61 The few courts that have considered the question have concluded that a product’s regulatory
status is not part of the medical information that physicians must disclose about a proposed
off-label treatment (unless it is administered in the context of research).62
At the same time, professional groups support disclosure in some situations. The AAP
Committee on Drugs advises physicians to use professional judgment in deciding when to
discuss with patients and parents a drug’s off-label status and its acceptance in the medical
community.63 Three European regulatory officials call on prescribers to discuss potential
benefits and harms of off-label applications with patients.64 An Australian group suggests
informing patients when a proposed off-label use is unusual or offered as a “last resort.”65 And
several legal commentators support a general legal requirement to disclose whether drugs are
FDA approved for a specific patient’s condition.66
Disclosure duties are designed to ensure that patients have sufficient information to evaluate
their treatment options. We think that reasonable patients would want to know when an off-
label application lacks strong support in the scientific or medical literature,67 when experience
suggests the use involves substantial risk, or when there is a possibility that insurers will refuse
to cover a costly off-label application. In clinical trials evaluating investigational products,
researchers are required to disclose the uncertainties and possible costs associated with trial
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participation.68 Similarly, patients should be given an opportunity to choose whether to accept
the uncertainties and possible costs associated with some off-label uses.
Ethical Considerations in Specific
Off-Label Situations—Off-label prescribing occurs in different situations that raise
different ethical issues. The appropriate approach to off-label prescribing can depend on
whether the use is new or old. Appropriate off-label prescribing can also depend on the urgency
of the patient’s situation and the availability of alternative treatment approaches. Off-label
prescribing in specific patient populations raises distinct ethical issues, as well.
Substantial uncertainty usually accompanies the off-label use of newly approved products.
Drugs and devices may be approved based on studies of relatively small groups followed for
a relatively short time. Even when physicians prescribe products according to the label,
previously undiscovered risks can emerge once products enter the clinical arena.69 The
possibility of undiscovered risks also exists when recently approved products are prescribed
off label.70
Novel off-label uses of both newly approved and older products typically present substantial
uncertainty about effectiveness, as well. As the American College of Physicians Ethics Manual
advises, physicians considering an unprecedented off-label indication or dosage “should
consult with peers, an institutional review board, or other expert group to assess the risks,
potential adverse outcomes, potential consequences of foregoing a standard therapy, and
whether the innovation is in the patient’s best interest.”71 Physicians prescribing products for
innovative off-label uses should tell patients about the unknowns, monitor them closely, and
begin collecting formal study data as soon as possible. An example of this approach is the
ongoing study of thalidomide, approved in 1998 for treating complications of leprosy, as an
anti-tumor agent.72
Some older products have been routinely prescribed off label for many years. Much off-label
prescribing in this category may benefit patients, but some of it may not.73 History
demonstrates that “without a formal method of evaluation, some widely adopted applications
of technologies can be nonbeneficial or even harmful to patients.”74 For example, the recent
increase in studies of off-label medication uses in children has produced label revisions that
change previously accepted prescribing practices.75
Even established off-label prescribing needs a solid evidentiary foundation. One problem in
this area is that product manufacturers often lack financial incentives to sponsor research on
older products, because the products are no longer protected by patent or are widely prescribed
without formal supplemental approval.76 As a result, it may be necessary to seek government
or other noncommercial support for research on off-label uses of older products. Another option
is for government agencies and professional organizations to conduct systematic reviews of
the existing evidence about off-label uses of older products.77
Off-label prescribing can also have different objectives. An off-label use may be the only
treatment option for seriously ill patients. In these circumstances, off-label prescribing can be
ethically justified on the basis of evidence that would be considered inadequate in other
contexts. For less seriously ill patients, off-label prescribing should have a stronger evidentiary
basis.78 And prescribing products off-label to improve patients’ appearance or lifestyle is
ethically justifiable only when very strong evidence demonstrates product safety. The goal
should be to avoid repeating incidents like the one involving dexfenfluramine, in which a drug
approved for obese patients whose weight put them at high risk of other illnesses was rapidly
prescribed for a broader range of patients who wanted to lose weight. Soon it became clear that
the drug could cause pulmonary hypertension and cardiac valve disease, and it was withdrawn
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from the market.79 But by that time, some patients taking the drug for cosmetic reasons had
suffered serious harm.80
Most off-label prescribing has clear therapeutic goals, and in certain practice areas, off-label
prescribing is both extremely common and necessary. For example, physicians treating patients
with rare (“orphan”) diseases rely heavily on off-label prescribing. Commercial sponsors lack
financial incentives to develop products for small populations and the small number of people
with these diseases makes it impossible to evaluate products according to ordinary clinical trial
criteria.81 During the 1980s, Congress passed legislation creating incentives for manufacturers
to develop products aimed at orphan diseases,82 but there are still many rare diseases lacking
effective approved therapies.83
Off-label use can be justified in these cases, but evidence about safety and effectiveness is just
as important for this patient population as it is for others. Data-gathering methods must be
flexible, but systematic study is often possible. Indeed, in approving products aimed at treating
orphan diseases, the FDA has accepted the results of trials involving as few as eight people as
adequate evidence of safety and effectiveness.84
Off-label prescribing is also common in pediatric, obstetric, and geriatric practice. Relatively
few prescription drugs on the market include labeling information about appropriate use in
these groups.85 This problem can be traced to sponsors’ and researchers’ reluctance (often
based on liability fears) to enroll minors, pregnant women, and elderly people in drug trials, a
reluctance that persists despite policy actions to promote research in underrepresented
populations.86
The failure to study these populations exposes patients to risks from drugs and dosages
presenting distinct risks to certain groups. For example, there is growing recognition that off-
label use of selective serotonin reuptake inhibitors for psychiatric disorders in young people
may increase the risks of suicidal thinking and depression.87 The failure to include children,
pregnant women, and older people in studies can also deprive patients of possibly beneficial
therapies, because physicians may hesitate to prescribe off label in light of the uncertain effects
in these populations. Children, elderly people, and pregnant women should have access to
treatments grounded in evidence-based data. The medical community should continue to
advocate for high-quality research evaluating product safety and effectiveness in these major
patient populations.
Policy Reforms
A former FDA official has criticized the agency for taking a “hear-no-evil, see-no-evil approach
to the off-label use of drugs.”88 Recent congressional action could improve this situation. The
FDA Amendments Act of 200789 made three changes to the FDCA that are relevant to off-
label prescribing.90
First and most significantly, the Act strengthened the postmarketing surveillance system
governing approved products. Congress increased funding for the FDA division charged with
monitoring the safety of approved drugs. Lawmakers also increased funding for the adverse
event reporting system, with the aim of creating an active monitoring system to replace the
current dependence on product manufacturers, physicians, and patients to report problems.
Other revisions in federal law will enable the agency to use information from large clinical
databases to evaluate product safety, including off-label uses.91 And the 2007 Act gives the
agency clear authority to order manufacturers to undertake post-approval studies so that risks
can be identified earlier than in the past. All of these measures could generate more information
about patients receiving products off label, thus improving the evidence base for off-label
prescribing.
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Second, the 2007 Act requires public registration of many industry-sponsored studies, which
could increase professional and public access to study information about off-label uses. The
revision will make it harder for manufacturers to conceal unfavorable results of such studies,
as some have done in the past.92 A third set of revisions increases the agency’s authority to
intervene when marketed products appear harmful to patients. The 2007 law empowers FDA
to mandate label changes to reflect newly discovered risks. It also authorizes FDA to restrict
the use of drugs known to be risky through limiting drug distribution to physicians with
specialized training.93
In 2009, the FDA adopted another new policy relevant to off-label prescribing. The agency
published a (nonbinding) guidance with FDA recommendations for “Good Reprint
Practices.”94 The guidance replaces the previous statutory provisions permitting manufacturers
to distribute enduring materials about off-label uses, which expired in 2006. It recommends
that manufacturers distribute articles published in peer-reviewed journals with independent
editorial boards and policies requiring full disclosure of “any conflict of interest or
biases.”95 It advises against distributing articles in manufacturer-funded special supplements
or publications. The guidance contains other provisions designed to ensure that distributed
materials contain high-quality information about off-label uses.96 But the guidance fails to
recommend or require that manufacturers work toward FDA approval of the uses discussed in
the enduring materials. It also omits the previous requirement for manufacturers to give the
FDA an opportunity to review the materials before they are given to physicians.
In issuing nonbinding recommendations and omitting the supplemental approval and prior
review requirements, the FDA was probably attempting to avoid First Amendment challenges
to the policy. Indeed, after the litigation challenging the previous law governing off-label
promotion, the FDA reportedly stopped enforcing those requirements.97 Nevertheless, leading
medical journals have published commentaries criticizing the FDA’s guidance.
Critics of the guidance say that selective publication of studies, manipulation of the literature,
and an inadequate knowledge base keep the published peer-reviewed literature from supplying
adequate information on the safety and effectiveness of off-label uses. Because of these
problems, they argue, manufacturers should be prohibited from distributing peer-reviewed
materials to physicians.98 The critics, however, underestimate the First Amendment problems
with imposing severe restrictions on distribution of scientific and medical publications about
off-label uses. They also assume that physicians will make better prescribing decisions if
manufacturers are prohibited from distributing enduring materials about off-label uses. Such
a ban might reduce the incidence of off-label prescribing, for it could reduce the number of
physicians aware of potential off-label applications. Off-label prescribing would still occur,
however, and physicians would rely on the peer-reviewed literature, as well as less rigorous
information sources, such as expert opinion and anecdotal evidence, to guide that prescribing.
99
The real value of government limits on off-label promotional activities is that they give
manufacturers an incentive to sponsor the research needed to determine whether off-label uses
are safe and effective. A more direct approach to promoting patients’ interests would be to
require manufacturers to submit more off-label uses for FDA review. Consistent with this view,
several commentators discuss the possibility of new statutory provisions authorizing the FDA
to mandate safety and effectiveness data for off-label uses that are widespread or based on
questionable evidence.100 Because this approach would regulate conduct, rather than speech,
it would avoid First Amendment challenges. Congress and the FDA would have to develop a
plan for implementing such a review requirement, but it could be a more effective way to
protect patients than measures that attempt to curb distribution of enduring materials on off-
label uses.
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Physicians and policymakers concerned about inappropriate off-label prescribing offer other
ideas for government actions that could improve the current situation. The FDA could simplify
the requirements for adding new uses to the approved product label or allow labels to include
more information about off-label uses.101 The agency could also analyze and distribute reports
about the evidence on selected off-label uses and require manufacturers seeking initial product
approval to present information about potential off-label uses.102 Congress could create
financial incentives, such as an additional period of market exclusivity, for manufacturers
sponsoring research on widespread or promising off-label uses.103 Federal officials could adopt
more rigorous policies on reimbursement for off-label uses, limiting Medicare and Medicaid
payments to off-label uses that are either supported by solid evidence or administered in the
context of clinical trials evaluating their safety and effectiveness.104
Conclusion
Without solid evidence, off-label prescribing can expose patients to harm. In the current debate,
the medical community often holds the FDA responsible for the problems with off-label
prescribing, while FDA officials expect the medical profession to ensure appropriate off-label
prescribing. But improving the quality of off-label prescribing will require action from both
groups.
Members of medical profession will likely remain essential gatekeepers to off-label
prescribing. As long as the regulatory system gives physicians the freedom to prescribe off
label, patients will depend on the medical profession to exercise this freedom responsibly. The
medical community should more actively promote efforts to identify appropriate and
inappropriate off-label prescribing and professional societies should urge members to limit off-
label prescribing to situations in which it is ethically justified.105 At the same time, members
of Congress and FDA officials should recognize a more affirmative role for government
oversight in this area. FDA officials should use their new legal powers to detect and publicize
problems with off-label use more effectively than they have in the past. Congress should
consider whether additional measures are needed to deter inappropriate off-label prescribing.
Patients need access to beneficial off-label treatments, but they also need protection from risky
and ineffective interventions. With a robust approach to professional oversight and policy
efforts to better evaluate the benefits and harms of specific off-label applications, physicians
and officials can fine tune off-label prescribing and promote the best interests of patients.
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